Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Eltrombopag Choline

FDA-approved product (tablet, oral), marketed as Alvaiz, Eltrombopag Olamine, Promacta and 1 more.

Registered studies
24
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Eltrombopag Choline
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Aplastic anemia
  • Autoimmune thrombocytopenic purpura
  • Chronic hepatitis C virus infection
  • Severe aplastic anemia
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis50.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Eltrombopag Choline in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-9.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-10.9 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Eltrombopag Choline with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Sequential rhTPO and Eltrombopag Following Glucocorticoids for Severe Adult ITP

    NCT07189910 · start 2025-12-01

    Registered record
    Registry ID
    NCT07189910
    Conditions
    Primary Immune Thrombocytopenia (ITP)
    Interventions
    Eltrombopag; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2027-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Immune Thrombocytopenia (ITP)
    InterventionEltrombopag; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag

    NCT07198672 · start 2025-10-31

    Registered record
    Registry ID
    NCT07198672
    Conditions
    HER2-positive Breast Cancer
    Interventions
    Herombopag
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2025-10-31
    Completion
    2028-10-31
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHER2-positive Breast Cancer
    InterventionHerombopag
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Study on the Short-term Efficacy and Safety of Recombinant Human Thrombopoietin Combined With Immunosuppressant Sequential Eltrombopag Ethanolamine Dry Suspension in the Treatment of SAA/TD-NSAA

    NCT07001397 · start 2025-06-23

    Registered record
    Registry ID
    NCT07001397
    Conditions
    Aplastic Anemias
    Interventions
    EPAG-pfos
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2025-06-23
    Completion
    2027-03-23
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAplastic Anemias
    InterventionEPAG-pfos
    PhasePhase 3
    Registry statusNot yet recruiting

  • Observational Study: Hetrombopag for Platelet Recovery in Haploidentical HSCT

    NCT07003269 · start 2024-09-01

    Registered record
    Registry ID
    NCT07003269
    Conditions
    Thalassemia in Children
    Interventions
    Hetrombopag
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2024-09-01
    Completion
    2026-04-30
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThalassemia in Children
    InterventionHetrombopag
    PhaseNot recorded
    Registry statusCompleted

  • Eltrombopag for Peripheral Blood Stem Cell Harvest

    NCT05961410 · start 2023-08-15

    Registered record
    Registry ID
    NCT05961410
    Conditions
    Lymphoma; Peripheral Blood Stem Cell Transplantation
    Interventions
    Eltrombopag olamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-08-15
    Completion
    2026-03-01
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Peripheral Blood Stem Cell Transplantation
    InterventionEltrombopag olamine
    PhasePhase 2
    Registry statusRecruiting

  • Bioequivalence Study of Eltrombopag Olamine Tablets in Healthy Subjects in the Fed State

    NCT06768619 · start 2023-03-20

    Registered record
    Registry ID
    NCT06768619
    Conditions
    Thrombocytopenia
    Interventions
    Group 1: single-dose of test formulation+single-dose of reference formulation; Group 2: single-dose of reference formulation+single-dose of test formulation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2023-03-20
    Completion
    2023-04-27
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia
    InterventionGroup 1: single-dose of test formulation+single-dose of reference formulation; Group 2: single-dose of reference formulation+single-dose of test formulation
    PhaseNot applicable
    Registry statusCompleted

  • A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts

    NCT05583838 · start 2022-11-22

    Registered record
    Registry ID
    NCT05583838
    Conditions
    Previously Treated Primary Immune Thrombocytopenia
    Interventions
    rhTPO; Eltrombopag
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2022-11-22
    Completion
    2024-07-16
    Enrolment
    157

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPreviously Treated Primary Immune Thrombocytopenia
    InterventionrhTPO; Eltrombopag
    PhasePhase 4
    Registry statusCompleted

  • Bioequivalence Test of Eltrombopag Olamine Tablets in Humans Under Fasting State

    NCT06768632 · start 2020-01-02

    Registered record
    Registry ID
    NCT06768632
    Conditions
    Thrombocytopenia
    Interventions
    Group 1: single-dose of test formulation+single-dose of reference formulation; Group 2: single-dose of reference formulation+single-dose of test formulation
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2020-01-02
    Completion
    2023-12-30
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia
    InterventionGroup 1: single-dose of test formulation+single-dose of reference formulation; Group 2: single-dose of reference formulation+single-dose of test formulation
    PhaseNot applicable
    Registry statusCompleted

  • Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

    NCT02071901 · start 2014-08-14

    Registered record
    Registry ID
    NCT02071901
    Conditions
    Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22); Adult Acute Myeloid Leukemia With t(16; 16)(p13; q22); Adult Acute Myeloid Leukemia With t(8; 21)(q22; q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Secondary Acute Myeloid Leukemia
    Interventions
    eltrombopag olamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-08-14
    Completion
    2019-01-06
    Enrolment
    31

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7) +20 more
    Interventioneltrombopag olamine
    PhasePhase 2
    Registry statusCompleted

  • A Rollover Study to Provide Continued Treatment With Eltrombopag

    NCT01957176 · start 2013-10-15

    Registered record
    Registry ID
    NCT01957176
    Conditions
    Thrombocytopaenia
    Interventions
    Eltrombopag (ELT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-10-15
    Completion
    2022-02-23
    Enrolment
    22

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopaenia
    InterventionEltrombopag (ELT)
    PhasePhase 4
    Registry statusCompleted

  • Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant

    NCT01927731 · start 2013-10-14

    Registered record
    Registry ID
    NCT01927731
    Conditions
    Bone Marrow Transplantation Recipient; Cord Blood Transplant Recipient; Hematopoietic Cell Transplantation Recipient
    Interventions
    Eltrombopag Olamine; Laboratory Biomarker Analysis
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-10-14
    Completion
    2023-06-06
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBone Marrow Transplantation Recipient; Cord Blood Transplant Recipient; Hematopoietic Cell Transplantation Recipient
    InterventionEltrombopag Olamine; Laboratory Biomarker Analysis
    PhasePhase 2
    Registry statusCompleted

  • A Long-term Safety Study of Eltrombopag in Pediatric Patients With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)

    NCT02201290 · start 2013-06-18

    Registered record
    Registry ID
    NCT02201290
    Conditions
    Purpura, Thrombocytopenic, Idiopathic
    Interventions
    Eltrombopag Tablets; Eltrombopag PfOS
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-06-18
    Completion
    2017-07-04
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopenic, Idiopathic
    InterventionEltrombopag Tablets; Eltrombopag PfOS
    PhasePhase 3
    Registry statusCompleted

  • Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia

    NCT01772420 · start 2012-10

    Registered record
    Registry ID
    NCT01772420
    Conditions
    Adult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia
    Interventions
    Eltrombopag Olamine; Laboratory Biomarker Analysis; Lenalidomide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-10
    Completion
    2020-07-09
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia
    InterventionEltrombopag Olamine; Laboratory Biomarker Analysis; Lenalidomide
    PhasePhase 2
    Registry statusCompleted

  • Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs)

    NCT01610180 · start 2012-06

    Registered record
    Registry ID
    NCT01610180
    Conditions
    Purpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Autoimmune Thrombocytopenia; Chronic Lymphocytic Leukemia; Non Hodgkin's Lymphoma
    Interventions
    Eltrombopag Olamine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-06
    Completion
    2018-06-30
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPurpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Autoimmune Thrombocytopenia; Chronic Lymphocytic Leukemia +1 more
    InterventionEltrombopag Olamine
    PhasePhase 2
    Registry statusCompleted

  • Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia

    NCT01550185 · start 2012-05

    Registered record
    Registry ID
    NCT01550185
    Conditions
    Adult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13; q22); Adult Acute Myeloid Leukemia With t(16; 16)(p13; q22); Adult Acute Myeloid Leukemia With t(8; 21)(q22; q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia
    Interventions
    eltrombopag olamine; standard follow-up care
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2012-05
    Completion
    2014-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdult Acute Basophilic Leukemia; Adult Acute Eosinophilic Leukemia; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0) +18 more
    Interventioneltrombopag olamine; standard follow-up care
    PhasePhase 1
    Registry statusTerminated